In developments reported on June 2, 2026, Tuesday’s reporting placed the item within ongoing policy and market developments. The US FDA approved Wockhardt’s antibiotic Zaynich (cefepime and zidebactam) on May 30, 2026 for complicated urinary tract infections in adults.
Related briefings added that india’s DCGI approved Zaynich on May 27, 2026. Wockhardt said Zaynich is the first new chemical entity fully developed and commercialized by an Indian pharma company to receive US FDA approval.
Subsequent updates explained that phase 3 data showed an 89.0% composite cure rate versus 68.4% for meropenem in cUTI patients. Wockhardt expects basic US patent protection until 2032 and overall US exclusivity until about 2038 with extensions.
Agencies indicated more information would be released on scheduled dates.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.business-standard.com/markets/wockhardt-patent